The Anabolic Effect Of Perioperative Nutrition With Insulin In Patients Undergoing CABG
Coronary Artery Disease
About this trial
This is an interventional supportive care trial for Coronary Artery Disease focused on measuring Catabolic response, Amino Acids, Insulin
Eligibility Criteria
Inclusion Criteria:
- Patients scheduled for elective CABG
Exclusion Criteria:
- Severe malnutrition (weight loss >20% in preceeding 3 months, low albumin level <35 g/L and body mass index <20 kg/m2), obesity (body mass index >35 kg/m2), chronic liver disease (cirrhosis, documented chronic viral hepatitis and abnormal liver function tests), left ventricular ejection fraction <30%, active cancer, dialysis, <18 years of age.
Sites / Locations
- McGill University Health Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Insulin
Insulin and amino acids
Insulin and hyperaminoacidemia
hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L. Amino Acids (AA) in amounts to preserve normal AA
hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L. AA in amounts to increase AA plasma concentrations to supra-normal levels (hyperaminoacidemia)